Curium Agrees to Buy Lantheus for Up to $8 Billion

Curium agreed to acquire Lantheus Holdings (NASDAQ: LNTH) for as much as $8 billion in a transaction that would combine their radiopharmaceutical diagnostic and therapeutic businesses.

The companies said the combined organization would operate across oncology, neurology and cardiology and serve patients in more than 70 countries. Curium would add Lantheus’ U.S. radiodiagnostics operations to its theranostics portfolio, manufacturing network and radioligand therapy pipeline. Under the agreement, Curium US Holdings will pay Lantheus investors $102.50 in cash for each outstanding share at closing. Shareholders will also receive non-transferable contingent value rights tied to specified commercial milestones for Lantheus products through 2030.

The contingent rights could provide additional cash payments of up to $12 per share, bringing the maximum consideration to $114.50 per share.

The companies valued the transaction at up to approximately $8 billion. The maximum per-share payment is about 14.9% above Lantheus’ latest closing price of $99.64.

Using May 21, 2026, the final trading day before the first media report of a potential sale, the companies said the total consideration represents a 38% premium to Lantheus’ unaffected 60-day volume-weighted average price and a 29% premium to its unaffected 30-day volume-weighted average price. It also represents a 21% premium to the company’s unaffected closing price on that date.

Lantheus’ board unanimously approved the transaction.Curium CEO Renaud Dehareng said the acquisition would expand the company’s U.S. presence by adding Lantheus’ commercial infrastructure, F18-based prostate diagnostic franchise and diagnostic products used in neurology and echocardiography.

Lantheus CEO Mary Anne Heino said the agreement reflected the radiopharmaceutical business the company had developed over seven decades.

About Curium and Lantheus

Curium develops, manufactures and supplies radiopharmaceutical products used in cancer diagnosis and treatment. Its operations include diagnostic imaging products, targeted radioligand therapies and a global manufacturing platform.

Lantheus Holdings (NASDAQ: LNTH) is a radiopharmaceutical-focused company whose products are used to detect, treat and monitor disease. Its portfolio includes diagnostic products serving oncology, neurology and cardiovascular care.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.